Search

everythinglearnresearchcommunity

for

Search:↓

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

People are excited about a new hair loss treatment, PP405, and some suggest using Twitter to increase its visibility. Current treatments mentioned include finasteride, minoxidil, and dutasteride, but skepticism remains about the effectiveness of new treatments.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

Using PRP or Exosome treatments alongside Finasteride/Dutasteride and Minoxidil may not significantly enhance results. Dutasteride and oral Minoxidil are considered more effective options.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

A 26-year-old man with diffuse alopecia is using electric scalp massage, dermastamp, and multivitamins for treatment but is intolerant to finasteride. A dermatologist recommended PRP and mesotherapy with exosomes and dutasteride.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

The conversation is about finding a source for topical valproic acid for hair regrowth. The user mentions PP405 and the unavailability of products from certain suppliers.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

The user is currently using 0.025% Pantostin but plans to switch to 0.1% Alfatradiol. They will also use high-dose Kx826, high-dose Minoxidil, and aggressive microneedling for hair regrowth.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.

The user started using finasteride, minoxidil, and biotin for male pattern baldness (MPB) and is experiencing rapid thinning. They are questioning if low blood flow to the head could be contributing to their hair loss.

The conversation discusses hair loss and queries the effectiveness of treatments like PRP, Exosome therapy, peptides, and Stem Cell therapy. Specific treatments like Minoxidil, finasteride, and RU58841 are also mentioned.

The conversation discusses the potential of verteporfin in treating hair loss, with some users reporting positive results and speculating that it could lead to a cure for baldness. Others are skeptical, and there's a debate on the effectiveness of verteporfin for regrowing hair and reducing transplant scars.

A 30-year-old male has been experiencing hair loss despite using Dutasteride 0.5mg and PRP for 15 months, with no success. He is considering a hair transplant but is advised to stabilize hair loss first and explore other treatments like topical Minoxidil or combined therapies.

Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.

Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.

Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.